Pelvic congestion syndrome (PCS) is a pathological condition characterized by impaired venous blood outflow from the pelvic organs, leading to venous congestion in the pelvic area. This condition can cause various clinical manifestations, the most common of which are pelvic pain, a feeling of heaviness, varicose veins of the lower extremities, and menstrual irregularities in women. The syndrome is common in young women and is associated with factors such as pregnancy, prolonged standing or sitting, and hereditary predisposition factors.
History of the disease and interesting historical facts
Pelvic congestion syndrome was first described in 1975 by the Italian phlebologist G. Gradino. Research into its damaging aspects continued over the following decades, which contributed to the formation of the term "pelvic congestion syndrome". Observations show that a significant increase in the number of cases of this syndrome is associated with the growing popularity of an active lifestyle, as well as with changes in the social status of women. Surprisingly, in the history of medicine there are references to similar manifestations as early as the 19th century, when doctors paid attention to similar symptoms in women, but until the development of a modern understanding of this syndrome, it was not discussed.
Epidemiology
According to various studies, the prevalence of pelvic venous congestion syndrome ranges from 5% to 25% among women of reproductive age. It has been established that this syndrome is more often diagnosed in women who have already had a pregnancy, as well as in those who suffer from chronic diseases associated with the venous system. The incidence of cases in women with a family history of venous diseases also increases significantly. Some studies show that gender plays a key role, since this syndrome is almost never found in men.
Genetic predisposition to this disease
Current research suggests that there is a genetic predisposition to pelvic congestion syndrome. The main genes involved include:
- COL3A1 – mutations in this gene are associated with venous insufficiency;
- ENG – may lead to disruption of angiogenesis;
- THBD – associated with hemostasis disorders.
However, the mechanism of transmission of hereditary predisposition has not yet been fully studied, and additional research is needed for a deeper understanding of genetic mechanisms.
Risk factors for the development of this disease
There are several risk factors that may contribute to the development of pelvic congestion syndrome. These include:
- Sitting or standing for a long time;
- Obesity and overweight;
- Pregnancy and childbirth;
- Hereditary predisposition to venous diseases;
- Hormonal changes and taking oral contraceptives.
These factors can increase the likelihood of occurrence and aggravate the course of the disease, requiring special attention from doctors during diagnosis and treatment.
Diagnosis of this disease
Diagnosis of pelvic venous congestion syndrome includes several stages:
- Main symptoms: pain in the pelvic area, feeling of heaviness, varicose veins of the lower extremities, amenorrhea or dysmenorrhea;
- Laboratory tests: hormone levels, coagulogram;
- Radiological examinations: ultrasound examination (US) of the pelvic veins, magnetic resonance imaging (MRI);
- Other types of diagnostics: venography, computed tomography;
- Differential diagnosis: exclusion of other pelvic and breast diseases such as endometriosis or amenorrhea.
This multi-stage strategy allows for a reliable diagnosis and further treatment.
Treatment
Treatment of pelvic venous congestion syndrome can be conservative or surgical. Conservative methods include:
- Classic compression stockings to improve venous outflow;
- Pharmacological treatment, including venotonics;
- Lifestyle changes: increasing physical activity, working while standing or sitting with breaks;
- Manual and physical therapy methods.
Surgical methods include:
- Endovenous laser coagulation;
- Sclerotherapy;
- Phlebectomy.
The effectiveness of treatment largely depends on the correct diagnosis and choice of therapy method.
List of medications used to treat this disease
Drugs indicated for the treatment of pelvic venous congestion syndrome include:
- Detralex;
- Troxevasin;
- Aescusan;
- Curcumin;
- Phlebodia 600.
Each of these agents helps improve venous tone and reduce congestion.
Disease monitoring
Monitoring of patients with pelvic venous congestion syndrome includes regular medical examinations, assessment of symptom dynamics and, if necessary, treatment adjustments. The prognosis of the disease is favorable in most cases, provided that the doctor's recommendations are followed. However, some patients may experience complications:
- Chronic venous insufficiency;
- Deep vein thrombosis;
- Versalieva syndrome.
Chronic complications can significantly worsen the patient's quality of life.
Age-related features of the disease
Pelvic venous congestion syndrome most often occurs in women aged 20 to 50 years. In older women and men, the likelihood of developing the syndrome is significantly lower. In older patients, the venous system undergoes other changes, and the syndrome may manifest itself more gradually, with less pronounced symptoms.
Questions and Answers
- What is pelvic congestion syndrome? This is a disease associated with a violation of venous outflow from the pelvic organs, which leads to blood stagnation and various clinical manifestations.
- How is pelvic congestion syndrome diagnosed? Diagnosis includes symptom analysis, laboratory tests, ultrasound and radiological examinations.
- What risk factors can contribute to the development of this disease? These include prolonged sitting or standing, pregnancy, obesity, and hereditary predisposition.
- What treatment is indicated for pelvic venous congestion syndrome? Treatment can be either conservative (compression, medications) or surgical (laser coagulation, phlebectomy).
- What is the prognosis for this disease? The prognosis is usually favorable, especially if you seek medical help in a timely manner and follow the treatment prescribed by your doctor.
